The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis
- Conditions
- Scoliosis; Adolescence
- Interventions
- Drug: Alphacalcidol
- Registration Number
- NCT03582917
- Lead Sponsor
- University of Ioannina
- Brief Summary
The purpose of this current prospective study is to determine the role of vitamin D in the development and restoration of spinal deformities in adolescence.
- Detailed Description
The investigator will record the medical history of each patient and information such as age, body size (weight, height) and body mass index (BMI = kg / m \^ 2). Girls will also be given the time of appearance of menstruation, a factor that needs to be evaluated because the growth of the skeleton continues three years after its appearance. Patients will be subjected to Adam's Test, x-ray's and as well as lateral bending radiographs.In the first contact with each patient, will be evaluated bone density measured by DEXA as well as haematological testing including PTH, alkaline phosphatase (ALP), calcium (Ca), phosphorus( P ), Calcitonin and, of course, vitamin D (total and metabolite 25 (OH) D).
Each patient's follow-up will be completed in two years by a clinical examination every six months and a clinical, laboratory and radiological examination per year. Patients will be divided into two groups. In a group with patients with normal 25 (OH) D and in a second group with patients with low levels of 25 (OH) D. Members of the second group will receive substitution treatment with an appropriate formulation. The results will be collected and evaluated using statistical programme.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 80
- Idiopathic Adolescent Scoliosis
- Risser sign <3-4
- Neuromuscular diseases
- metabolic disease
- Liver, lung, thyroid and parathyroid gland disorders.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Alphacalscidol Alphacalcidol 0,5mg tablet by mouth, one each day for one year
- Primary Outcome Measures
Name Time Method 25(OH)D 48 weeks Measurement of the major metabolite of vitamin D
X - rays 48 weeks Cobb angle measurement
Dexa 48 weeks BMD and Z - score measurement
BMD (weight in kilograms, height in meters) 48 weeks weight and height will be combined to report BMI in kg/m\^2
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Papanikolaou General Hospital
🇬🇷Asvestochori, Greece
Department of Physical Medicine and Rehabilitation, University Hospital of Ioannina
🇬🇷Ioannina, Greece